These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 28623359)

  • 1. Allosteric modulatory effects of SRI-20041 and SRI-30827 on cocaine and HIV-1 Tat protein binding to human dopamine transporter.
    Sun WL; Quizon PM; Yuan Y; Zhang W; Ananthan S; Zhan CG; Zhu J
    Sci Rep; 2017 Jun; 7(1):3694. PubMed ID: 28623359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport.
    Midde NM; Yuan Y; Quizon PM; Sun WL; Huang X; Zhan CG; Zhu J
    J Neuroimmune Pharmacol; 2015 Mar; 10(1):122-35. PubMed ID: 25604666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRI-32743, a novel allosteric modulator, attenuates HIV-1 Tat protein-induced inhibition of the dopamine transporter and alleviates the potentiation of cocaine reward in HIV-1 Tat transgenic mice.
    Zhu J; Quizon PM; Wang Y; Adeniran CA; Strauss MJ; Jiménez-Torres AC; Patel P; Cirino TJ; Eans SO; Hammond HR; Deliscar LS; O'Hara P; Saini SK; Ofori E; Vekariya RH; Zhang S; Moukha-Chafiq O; Nguyen TH; Ananthan S; Augelli-Szafran CE; Zhan CG; McLaughlin JP
    Neuropharmacology; 2022 Dec; 220():109239. PubMed ID: 36126727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat-inhibited Dopamine Transport.
    Quizon PM; Yuan Y; Zhu Y; Zhou Y; Strauss MJ; Sun WL; Zhan CG; Zhu J
    J Neuroimmune Pharmacol; 2021 Dec; 16(4):854-869. PubMed ID: 33537927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of SRI-32743, a Novel Quinazoline Structure-Based Compound, on HIV-1 Tat and Cocaine Interaction with Norepinephrine Transporter.
    Jiménez-Torres AC; Porter KD; Hastie JA; Adeniran C; Moukha-Chafiq O; Nguyen TH; Ananthan S; Augelli-Szafran CE; Zhan CG; Zhu J
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions.
    Midde NM; Huang X; Gomez AM; Booze RM; Zhan CG; Zhu J
    J Neuroimmune Pharmacol; 2013 Sep; 8(4):975-87. PubMed ID: 23645138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational effects of human dopamine transporter at tyrosine88, lysine92, and histidine547 on basal and HIV-1 Tat-inhibited dopamine transport.
    Sun WL; Quizon PM; Yuan Y; Strauss MJ; McCain R; Zhan CG; Zhu J
    Sci Rep; 2019 Mar; 9(1):3843. PubMed ID: 30846720
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Jimenez-Torres AC; Hastie JA; Davis SE; Porter KD; Lei B; Moukha-Chafiq O; Zhang S; Nguyen TH; Ananthan S; Augelli-Szafran CE; Zhu J
    J Pharmacol Exp Ther; 2024 Sep; ():. PubMed ID: 39284625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism: the human dopamine transporter histidine 547 regulates basal and HIV-1 Tat protein-inhibited dopamine transport.
    Quizon PM; Sun WL; Yuan Y; Midde NM; Zhan CG; Zhu J
    Sci Rep; 2016 Dec; 6():39048. PubMed ID: 27966610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of human dopamine transporter in NeuroAIDS.
    Zhu J; Ananthan S; Zhan CG
    Pharmacol Ther; 2018 Mar; 183():78-89. PubMed ID: 28987321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanism of HIV-1 Tat interacting with human dopamine transporter.
    Yuan Y; Huang X; Midde NM; Quizon PM; Sun WL; Zhu J; Zhan CG
    ACS Chem Neurosci; 2015 Apr; 6(4):658-665. PubMed ID: 25695767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 transgenic rats display an increase in [(3)H]dopamine uptake in the prefrontal cortex and striatum.
    Zhu J; Yuan Y; Midde NM; Gomez AM; Sun WL; Quizon PM; Zhan CG
    J Neurovirol; 2016 Jun; 22(3):282-92. PubMed ID: 26501780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Histidine 547 of Human Dopamine Transporter in Molecular Interaction with HIV-1 Tat and Dopamine Uptake.
    Yuan Y; Quizon PM; Sun WL; Yao J; Zhu J; Zhan CG
    Sci Rep; 2016 Jun; 6():27314. PubMed ID: 27250920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study.
    Ferris MJ; Frederick-Duus D; Fadel J; Mactutus CF; Booze RM
    Neuroscience; 2009 Apr; 159(4):1292-9. PubMed ID: 19344635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes.
    Zhu J; Mactutus CF; Wallace DR; Booze RM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1071-83. PubMed ID: 19325033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Allosteric Modulator Southern Research Institute-32743 Reverses HIV-1 Transactivator of Transcription-Induced Increase in Dopamine Release in the Caudate Putamen of Inducible Transactivator of Transcription Transgenic Mice.
    Davis SE; Ferris MJ; Ananthan S; Augelli-Szafran CE; Zhu J
    J Pharmacol Exp Ther; 2023 Feb; 384(2):306-314. PubMed ID: 36456195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency.
    Rothman RB; Ananthan S; Partilla JS; Saini SK; Moukha-Chafiq O; Pathak V; Baumann MH
    J Pharmacol Exp Ther; 2015 Jun; 353(3):529-38. PubMed ID: 25788711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142.
    Moerke MJ; Ananthan S; Banks ML; Eltit JM; Freitas KC; Johnson AR; Saini SK; Steele TWE; Negus SS
    J Pharmacol Exp Ther; 2018 Nov; 367(2):222-233. PubMed ID: 30150482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function.
    Strauss MJ; Porter KD; Quizon PM; Davis SE; Lin S; Yuan Y; Martinez-Muniz GA; Sun WL; Zhan CG; Zhu J
    PLoS One; 2022; 17(9):e0275182. PubMed ID: 36170295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428, on HIV-1 Tat toxicity in rat fetal midbrain neurons.
    Aksenov MY; Aksenova MV; Silvers JM; Mactutus CF; Booze RM
    Neurotoxicology; 2008 Nov; 29(6):971-7. PubMed ID: 18606182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.